在怀孕期间用于抗血栓治疗的NET向纳米颗粒
Yijie Zhou1,2,3,4, Lin Xu1,2,3,4, Pingsong Jin5,2
1Department of Obstetrics, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
iScience
|May 17, 2024
概括
这项研究引入了新的纳米颗粒来治疗孕妇的深静脉血栓症 (DVT),提供了一个安全的,非侵入性的选择. 该疗法向激活的中性粒细胞,并降低与母亲血栓形成相关的风险.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 产科和妇科 产科和妇科
背景情况:
- 怀孕期间的深静脉血栓 (DVT) 构成严重的孕产妇健康风险,包括肺栓塞.
- 目前在怀孕期间对DVT的治疗选择缺乏足够的安全性和有效性.
- 中性细胞细胞外陷 (NET) 的形成越来越被认为是血栓形成的关键因素.
研究的目的:
- 开发和评估一种基于纳米粒子的新型治疗方法,用于怀孕期间的DVT.
- 调查向激活中性粒细胞的安全性和有效性,并减轻与血栓相关的并发症.
- 为了解决怀孕期间对安全有效的DVT治疗的未满足需求.
主要方法:
- 用中性粒细胞弹性酶 (NE) 结合进行表面修饰的纳米颗粒的创建,用于有针对性的输送.
- 使用普鲁士蓝色纳米粒子 (PBNP) 来清理反应性氧物种 (ROS) 并作为光热剂.
- 使用光热疗法 (PTT) 来破坏与血栓形成相关的纤维素网络结构.
主要成果:
- 开发的纳米粒子在体外和体内都有效向活性中性粒细胞.
- 普鲁士蓝色纳米粒子展示了ROS清理和光热能力用于纤维素网络破坏.
- 发现非侵入性光热疗法方法对母亲和胎儿都是安全的.
- 观察到由母体血栓形成引起的子宫内生长限制的显著缓解.
结论:
- 表面修饰的纳米颗粒提供了一个有希望的针对性治疗在怀孕期间的DVT.
- 这种非侵入性光热疗法为管理母亲血栓形成提供了安全有效的策略.
- 这种方法显示出减轻诸如子宫内生长限制等严重并发症的潜力.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
686
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
686
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
521
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
521
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
155
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
155
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
167
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
167